The development of Alzheimer's disease (AD) is closely connected with cholesterol metabolism. Cholesterol increases the production and deposition of amyloid-(A ) peptides that result in the formation of amyloid plaques, a hallmark of the pathology. In the brain, cholesterol is synthesized in situ but cannot be degraded nor cross the blood-brain barrier. The major exportable form of brain cholesterol is 24S-hydroxycholesterol, an oxysterol generated by the neuronal cholesterol 24-hydroxylase encoded by the CYP46A1 gene. We report that the injection of adeno-associated vector (AAV) encoding CYP46A1 in the cortex and hippocampus of APP23 mice before the onset of amyloid deposits markedly reduces A peptides, amyloid deposits and trimeric oligomers at 12 months of age. The Morris water maze (MWM) procedure also demonstrated improvement of spatial memory at 6 months, before the onset of amyloid deposits. AAV5-wtCYP46A1 vector injection in the cortex and hippocampus of amyloid precursor protein/ presenilin 1 (APP/PS) mice after the onset of amyloid deposits also reduced markedly the number of amyloid plaques in the hippo campus, and to a less extent in the cortex, 3 months after the injection. Our data demonstrate that neuronal overexpression of CYP46A1 before or after the onset of amyloid plaques significantly reduces A pathology in mouse models of AD.
INTRODUCTION
Alzheimer's disease (AD) is the most common neurodegenerative disease of the elderly but no e cient treatment is currently available. A hallmark of all forms of AD is an abnormal accumulation of amyloid-β (Aβ) peptides in speci c brain regions. 1 Aβ peptides are generated by sequential proteolytic processing of the amyloid precursor protein (APP) by β-site APP-cleaving enzyme 1 (BACE1) and γ-secretase. 2 Further to the identi cation of 4 isoform of apolipoprotein E (APOE) as the main risk factor for AD, 3 there is growing evidence that cholesterol regulates the generation and clearance of APP proteolytic products. 4, 5 Cholesterol content in cultured cells and in transgenic mouse models of AD is paralleled by the production of Aβ peptides. 6, 7 Moreover, senile plaques are enriched in cholesterol 8 and the postmortem analysis of AD brains revealed an abnormal retention of cholesterol in neurons. 9 Drugs that modify cholesterol homeostasis are currently considered as potential therapies for AD. Cholesterol synthesis inhibitors like statins reduce amyloid burden in guinea-pig and transgenic mouse models of the disease 10 but this positive e ect awaits validation in prospective clinical trials. 11 An inhibitor of acyl-coenzyme A: cholesterol acyltransferase was also shown to reduce amyloid pathology in APP23 mice, a mouse model of AD. 12 However, these drugs not only modify cholesterol metabolism in the brain but also in peripheral tissues and plasma.
Like all mammalian cells, neurons cannot degrade cholesterol by themselves and blood-brain barrier restricts its export out of the brain. 13 e major mechanism of cerebral cholesterol clearance involves the conversion of cholesterol into 24S-hydroxycholesterol by cholesterol 24-hydroxylase, an enzyme expressed only in neurons and encoded by the CYP46A1 gene.
14 24S-hydroxycholesterol can freely cross the blood-brain barrier and is degraded in the liver. Following interaction with liver-X receptors (LXRs), 24S-hydroxycholesterol regulates in vitro the expression of several adenosine triphosphate-binding cassette transporters (ABCA1, ABCA2, ABCG1, ABCG4, and ABCG5) and APOE genes involved in cholesterol transport and homeostasis in the brain. 15, 16 We hypothesized that increasing neuronal cholesterol 24-hydroxylase activity will reduce amyloidogenesis from APP. As no small molecule is able to stimulate cholesterol 24-hydroxylase activity in vitro or in vivo, we tested whether the brain delivery of CYP46A1 gene through injection of adeno-associated vector (AAV), before or a er the onset of amyloid plaques, could be a strategy to decrease the deposition of amyloid peptides. is hypothesis was evaluated: (i) before the onset of amyloid deposits in APP23 mice that develop memory de cits at 3 months and amyloid plaques at 6 months 17, 18 and (ii) a er the onset of amyloid deposits in APP/presenilin 1 (PS) mice that develop amyloid plaques at 2½ months and are characterized by a more severe phenotype. 19 Other viral vector approaches aiming at the same objective were previously chosen to deliver the neprilysin gene or small interfering RNAs targeting APP and BACE. [20] [21] [22] We report that the overexpression of CYP46A1 gene in hippocampus and cortex of APP23 mice from the age of 3 months improves their spatial memory at 6 months and markedly reduces amyloid deposits, Aβ 40 and Aβ 42 peptides and trimeric Aβ oligomers at 12 months. e overexpression of CYP46A1 gene in hippocampus and cortex of APP/PS presenilin 1 mice from the age of 3 months also reduces the number of amyloid plaques at 6 months.
Further in vitro studies performed in murine neuroblastoid (N2a) cells overexpressing a mutated human APP gene indicate that CYP46A1 overexpression diminishes the cholesterol concentration and the recruitment of APP and presenilin 1 (PSEN1), a component of γ-secretase complex, in lipid ra s.
Our results suggest that the cerebral delivery of CYP46A1 gene can speci cally reduce the cleavage of APP in vivo before or a er the onset of amyloid deposits and indicate that this approach could have potential therapeutic value for treatment of AD.
RESULTS
AAV-mediated expression of CYP46A1 increases 24S-hydroxycholesterol content in the brain of APP23 mice without global cholesterol change AAVs expressing wild-type (wt) (AAV5-wtCYP46A1, n = 11 females) or mutated (AAV5-mtCYP46A1, n = 11 females) human CYP46A1 cDNA tagged with the hemaglutinin (HA) epitope were injected in hippocampus, frontal, and parietal cortices of both hemispheres of 3-month-old APP23 mice. e mutant (mt) CYP46A1 protein contains a missense mutation (A1309C) that destroys its heme structure, resulting in the complete lack of cholesterol 24-hydroxylase activity (L. Pradier, unpublished results).
At age 6 (i.e., 4 months postinjection; n = 12) and 12 months (i.e., 10 months postinjection; n = 10), wt or mt CYP46A1 proteins showed comparable expression in neurons from the cerebral cortex and hippocampus of injected APP23 mice (Figure 1a,b) . Both wt and mt CYP46A1 proteins colocalized with the GRP78 Bip marker in the endoplasmic reticulum, as did the endogenous cholesterol-24-hydroxylase 23 ( Figure 1b) . With quantitative reverse transcriptase-PCR (RT-PCR), the level of CYP46A1 mRNA was found to be eightfold higher than the level of endogenous mouse CYP46A1 in APP23 mouse (data not shown). e overexpression of human CYP46A1 gene did not modify the expression of endogenous murine Cyp46A1 gene (data not shown). In comparison with the level observed in noninjected APP23 mice or APP23 mice injected with the AAV5-mtCYP46A1 vector, the 24S-hydroxycholesterol content increased twofold in the dissected cerebral cortex and hippocampus of mice injected with AAV5-wtCYP46A1 vector. is indicates that the recombinant wt CYP46A1 enzyme was fully active and that the mt CYP46A1 protein was inactive and did not disturb the activity of endogenous murine cholesterol 24-hydroxylase in APP23 mice. e concentrations of total cholesterol (Figure 1c ) and cholesteroyl esters (data not shown) remained however unchanged in the cerebral cortex and hippocampus of 12-month-old APP23 mice injected with AAV5-wtCYP46A1 or AAV5-mtCYP46A1 vectors.
We analyzed the expression of several important genes involved in cholesterol metabolism by quantitative RT-PCR. As shown in Figure 1d , the expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr) and sterol-binding protein 2 (Srebp2) gene increased by 1.6-fold but no change in acylcoenzyme A:cholesterol acyltransferase 1, low-density lipoprotein receptor (Ldlr), low-density lipoprotein-related protein 1 (Lrp1), lecithin:cholesterol acyltransferase (Lcat), and Niemann-Pick disease C1 (Npc1) gene expression was observed.
AAV5-wtCYP46A1 vector injection results in decreased amyloid deposition and A peptides production in APP23 mice
e neuronal overexpression of the CYP46A1 gene from the age of 3 months was associated with a marked reduction in the number of amyloid plaques (63 and 68%) and in the percentage of area occupied by amyloid deposits (73 and 70%) in the hippocampus and cerebral cortex of APP23 mice at 12 months of age (Figure 2a,b) . Most remaining amyloid deposits were concentrated in regions where very few or no cells expressed the wtCYP46A1 protein. Hematein-eosin staining did not reveal the presence of lymphocytic in ltrates that could arise from immune reaction against the AAV or the transgene expression (data not shown). Aβ 40 and Aβ 42 peptides assessed by enzymelinked immunosorbent assay decreased by 50 3 and 57 4%, respectively, in pooled cerebral cortex and hippocampus samples (Figure 2c) . Because of their reported high neuronal toxicity, 24, 25 amyloid oligomers were also analyzed by western blot.
e amount of hexameric and dodecameric Aβ oligomers were slightly reduced without reaching statistical signicance. However, trimeric Aβ oligomers were decreased by 50% in the sodium dodecyl sulfate and Triton fractions of AAV5-wtCYP46A1-injected mice (P < 0.05, Figure 2d ). As already observed in other mouse models of AD (except in 3xTg-AD mice at 20 months 26 ) , no dimeric aggregates could be detected with the 6E10 antibody in the brain homogenates of APP23 mice. 27, 28 ese results indicate that neuronal overexpression of the CYP46A1 gene before the onset of amyloid plaques has a clear bene cial e ect on the amyloidogenic processing of APP in APP23 mice at 12 months.
To determine whetherAPP processing was directly a ected by the overexpression of cholesterol 24-hydroxylase, we quanti ed the expression level of several genes of the amyloidogenic pathway and the amounts of APP cleavage products. In AAV5-wtCYP46A1-injected mice, the expression of Adam9, -10, -17 (three enzymes that were shown to have some α-secretase activity 29 ), Bace1 and Psen1 remained unchanged (data not shown). Western blotting experiments showed that the amount of α-secretase product C83 was una ected whereas the β-secretase product C99 increased by 40% in AAV5-wtCYP46A1-injected mice (Figure 2e,f) . APP intracellular domain (AICD) fragments generated by γ-cleavage were barely detectable (Figure 2e ) in treated APP23 mice, suggesting that CYP46A1 expression induced a decreased cleavage of APP C-terminal fragments (CTFs) by γ-secretase in vivo.
Quantitative RT-PCR experiments also failed to detect any induction of LXR target genes expression such as Abca1, Abca2, Abcg1, Abcg4, Abcg5 and ApoE (data not shown), suggesting that the bene cial e ect of cholesterol 24-hydroxylase overexpression on Aβ production in vivo was not due to the induction of LXR pathway.
Neuronal overexpression of CYP46A1 decreases microgliosis and astrocytosis and improves cognitive deficits in APP23 mice e number of microglial Iba-1 positive cells was reduced by 41 7 and 46 4%, respectively in the cerebral cortex and hippocampus of APP23 mice injected with AAV5-wtCYP46A1 vector (Figure 3a) . Similarly, the number of glial brillary acidic protein -positive cells was reduced by almost 50% in APP23 mice injected with AAV5-wtCYP46A1 vector (Figure 3b) . As amyloid plaques were shown to induce microglial recruitment and astrocytosis in APP23 mice, 30 this decrease could be related to the lower number of amyloid deposits observed in AAV5-wtCYP46A1-injected animals. e cerebellum, a brain region that physiologically contains microglial cells 31 and lacks amyloid deposits in APP23 mice, was chosen as a control brain region. As expected, no change in the recruitment of Iba-1 and glial brillary acidic protein-positive cells was observed in the cerebellum of treated APP23 mice (Figure 3a,b) . ese results indicate that neuronal overexpression of the CYP46A1 gene before the onset of amyloid plaques has a clear bene cial e ect on microgliosis and astrocytosis associated with amyloid deposits in APP23 mice at 12 months.
APP23 mice develop moderate cognitive de cits at 3 months of age, whereas amyloid deposits are only detected in their brain at 6 months. 18 To evaluate the e ects of AAV5-wtCYP46A1 vector injection on cognitive functions, mice were tested at 6 months using the Morris water maze (MWM) procedure. All mice injected with either AAV5-wtCYP46A1 or AAV5-mtCYP46A1 vectors showed improved performances during the acquisition phase (P < 0.001) (Figure 3c,d) . We observed however a signi cant e ect of AAV5-wtCYP46A1 injection on path length parameter (P = 0.05, two-way repeated measures-analysis of variance) with no signi cant interaction between vector injection and trial block (P = 0.583) (Figure 3c ). e absence of treatment e ects on swim speed (Figure 3e ) indicated that the improvement in path length was not due to a better motor performance. We observed no signi cant e ect of vector injection on escape latency (Figure 3d) . During the probe trial, mice injected with AAV5-wtCYP46A1 vector did not spend more time in the target quadrant (Figure 3f) but they crossed more frequently (1.4 0.4) the previous platform position than sham-treated APP23 mice (0 0, P = 0.018) indicating that their spatial memory was improved. As cognitive evaluation can only be performed on naive mice, no futher testing could be performed on the same treated mice at 12 months of age. In agreement with the bene cial e ect of CYP46A1 overexpression on Aβ oligomers production, these results indicate that neuronal overexpression of the CYP46A1 gene before the onset of amyloid plaques improves cognitive functions in APP23 mice at a time amyloid deposits just begin to be detectable in their brain.
AAV5-wtCYP46A1 vector injection decreases the number of amyloid deposits in APP/PS mice
APP/PS mice develop a more severe phenotype than APP23 mice with an onset of amyloid deposits at 2½ months. To determine whether neuronal overexpression of CYP46A1 could be of bene t once amyloid pathology has become obvious, AAV5-wtCYP46A1 (n = 5 females) or AAV5-mtCYP46A1 (n = 5 females) vectors were injected in the hippocampus and cerebral cortex of both hemispheres of 3-month-old APP/PS mice. At this age, amyloid deposits are already present in the brain of these animals ( Figure 4a ). e number of amyloid deposits decreased by 54% (P < 0.05) in the hippocampus of APP/PS mice treated with the AAV5-wtCYP46A1 vector, and analyzed at 6 months (Figure 4b) . A less marked and signi cant decrease (26%; P < 0.065) of amyloid deposits was observed in the cerebral cortex of treated animals.
In vitro overexpression of CYP46A1 decreases the amount of cholesterol and PSEN1 in detergentresistant membranes isolated from murine neuroblastoid cells expressing mutated human APP e injection of AAV5-wtCYP46A1 vector in APP23 mice was associated with a signi cant decrease of Aβ peptide production without a ecting the global cholesterol homeostasis or the LXR pathway. To get further insight on the mechanisms by which CYP46A1 overexpression reduces AICD fragments generated by γ-cleavage in vivo, we engineered murine neuroblastoid N2a cell lines to constitutively overexpress the human APP gene harboring the Swedish and London mutations (APPsl). We selected clone 17 (further called N2a-APP17) that was found to secrete the highest levels of Aβ 40/42 Figure S1a) and demonstrated that this clone had a decreased expression of endogenous murine CYP46A1 gene (data not shown) and a 43% reduction of 24S-hydroxycholesterol content (Supplementary Figure S1b) . Identical results were observed in the two other (N2a-APP11 and -12) analyzed cells lines (data not shown). In contrast to what was observed in N2a-APP cells, no decrease in the 24S-hydroxycholesterol content could be detected in nontreated APP23 mice, as already published by Lutjohann.
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To restore the expression of cholesterol-24-hydroxylase, we engineered N2a-APP17 cells to overexpress the human CYP46A1 gene. We obtained two cell lines, called N2a-APP-CYP-A and -B that overexpressed the CYP46A1 transgene at di erent levels and showed an increase of 24S-hydroxycholesterol with no signicant change in total cholesterol level (Supplementary Figure S1c) . In these cells, a decrease of Aβ 40 and Aβ 42 peptides secretion was observed, which was inversely proportional to the increased 24S-hydroxycholesterol content (r 2 = 0.91) (Supplementary Figure S1d) . Aβ 42 peptides were barely detectable in the N2a-APP-CYP-B cells that expressed the highest level of CYP46A1 gene. As previously observed in APP23 mice injected with AAV5-wtCYP46A1 vector, this e ect was not due to modi cations of the expression of APPsl transgene nor of murine Adam9, Adam10, Adam17, Bace1, and Psen1 involved in APP processing, nor of Hmgcr, the rate limiting enzyme of cholesterol synthesis, and nor of adenosine triphosphate-binding cassette transporter A1 (Abca1) and ApoE (data not shown).
To determine whether the e ect of cholesterol 24-hydroxylase overexpression in vitro was also associated with changes in γ-secretase cleavage in N2a-APP-CYP cells, we quanti ed the CTFs of APP by western blotting in crude cell extracts. e α-secretase cleavage product C83 content was not modi ed in N2a-APP-CYP-A and -B cells. e β-secretase cleavage product C99 peptide increased by 37% in N2a-APP-CYP-A cells and was reduced by 34% in N2a-APP-CYP-B cells, whereas the γ-secretase cleavage product AICD was lowered by 50-65% in both N2a-APP-CYP-A and -B cells (Figure 5a ). e concomitant decrease of AICD and increase of β-CTF in N2a-APP-CYP-A cells were consistent with the hypothesis that CYP46A1 overexpression could mostly act at the level of CTF cleavage by γ-secretase, as already observed in APP23 mice injected with AAV5-wtCYP46A1 vector. However, at higher level of expression, CYP46A1 also seemed to decrease, at least in vitro, β-CTF, suggesting an additional e ect on β-secretase activity in those experimental conditions.
Mounting evidence argues that lipid ra s, biochemically de ned as detergent-resistant membranes (DRMs), are the principal membrane microdomains in which the amyloidogenic processing of APP occurs. 33 Lipid ra s are enriched in cholesterol, and γ-secretase complex coresides with APP and β-secretase in these microdomains. [34] [35] [36] Changes in the content of cholesterol in lipid ra s can markedly in uence the production of Aβ. 7, 37 In N2a-APP17 cells overexpressing the CYP46A1 gene, the amount of cholesterol was decreased by 28 and 45% in the two otillin-2 positive DRM fractions of N2a-APP-CYP-A and -B cells, respectively (Figure 5b) . APP resides both in ra and nonra domains and the percentage of APP localized in the two otillin-2 positive DRM fractions of N2a-APP17 cells represented 40% of the total amount of APP (Figure 5c ). In the same enriched cholesterol fractions from N2a-APP-CYP-A and -B cells, the amount of BACE1 was not modi ed (data not shown) but APP was reduced by 32 and 45% and PSEN1, a component of γ-secretase, was lowered by 25 and 67%, respectively (Figure 5c ). Altogether these results suggest that the reduction of cholesterol in DRMs in N2a-APP17 cells overexpressing CYP46A1 leads to a decreased recruitment or stabilization of APP and PSEN1 in the same microdomains, resulting in a decreased cleavage of CTF by γ-secretase 
DISCUSSION
CYP46A1 encodes the cholesterol 24-hydroxylase, a master regulator of cerebral cholesterol metabolism. 14, 38 Our observations indicate that increasing CYP46A1 expression in the brain is a new mechanism for decreasing Aβ peptide production and amyloid deposits, the pathological hallmark of AD.
Brain tissue from AD patients shows a decreased number of neurons expressing cholesterol 24-hydroxylase, possibly because of neuronal degeneration. 39 Accordingly, 24S-hydroxycholesterol concentration is lowered in the cerebrospinal uid and peripheral circulation of AD patients at an advanced stage of the disease, 40 whereas it is increased at an earlier stage. 41 In our work, the cerebral delivery of human CYP46A1 gene via an AAV vector in APP23 mice before the onset of amyloid plaques induced 10 months later a twofold increase of 24S-hydroxycholesterol levels in the brain and a marked concomitant decrease of Aβ 40/42 peptides and amyloid deposits in the hippocampus and cerebral cortex. Microgliosis and astrogliosis were also diminished. As the accumulation of small Aβ oligomers is o en considered responsible for AD synaptic dysfunction, 24, 25 it may be of importance that trimeric Aβ oligomers, that were shown to fully inibit long-term potentiation, 42 were reduced in the brain of APP23 mice injected with the AAV-wtCYP46A1 vector.
Cognitive performances were also improved in treated APP23 mice at 6 months of age. Despite the di culties of MWM interpretation due to the variability of behavioral parameters, 43 we documented a statistical trend for an improved acquisition learning curve based on path length values, the most reliable parameter of MWM learning, as well as an improvement in spatial memory. is e ect was observed while amyloid deposits begin to be detectable in this AD mouse model.
Of note, short-term studies performed in APP/PS mice showed that the cerebral delivery of human CYP46A1 gene also decreases the number of amyloid deposits in the hippocampus when injections of AAV were performed a er the onset of amyloid pathology.
In APP23 mice, CYP46A1 overexpression was neither associated with a decrease of brain cholesterol and cholesteryl esters nor with the modi cation of the expression of genes regulating cholesterol metabolism. Only the Hmgcr and Srebp2 genes were shown to be slightly upregulated (1.6-fold), likely contributing to maintain the steady-state level of brain cholesterol.
Previous cell-based studies demonstrated that pharmacological concentrations of 24S-hydroxycholesterol could upregulate, through the activation of the LXR pathway, the expression of APOE and of ATP-binding cassette (ABC) transporter genes that control cholesterol tra cking between neurons and astrocytes. 15, 16 Moreover, the use of synthetic LXR ligands was shown to induce the expression of Abca1 and ApoE both in vitro and in vivo, 44, 45 thus modifying the lipidation status of APOE and its capacity to degrade Aβ. 46, 47 In our study, even we cannot completely exclude the possibility that the bene cial e ect of CYP46A1 overexpression was mediated by post-translational changes of APOE, this hypothesis seems unlikely because APOE lipidation is mostly under the control of Abca1 expression that remained una ected in APP23 mice treated with AAV-wtCYP46A1 vector. e absence of change in ApoE, Abca1, and other Abc transporter genes in APP23 mice injected with AAV-wtCYP46A1 vector clearly indicated that the bene cial e ect of CYP46A1 overexpression on amyloidogenic processing of APP was not mediated by the activation of the LXR pathway by 24S-hydroxycholesterol. ese results are in agreement with recent data showing that 22R-hydroxycholesterol, another natural ligand, is a weak partial agonist of LXR receptors 48 compared with synthetic molecules. However, as 24S-hydroxycholesterol concentration increased only twofold in the brain of treated APP23 mice, we cannot completely exclude that 24S-hydroxycholesterol can activate the LXR pathway in vivo, but at higher concentrations. e concomitant decrease of AICD and increase of β-CTF observed in APP23 mice and in N2a-APP cells overexpressing CYP46A1 suggest that the lower Aβ 40/42 peptides content could be caused by a decreased cleavage of APP CTFs by γ-secretase. Cholesterol was shown to regulate the generation of Aβ peptides, particularly in lipid ra s in which APP and γ-secretase components coreside. 35, 36 Although the data obtained in N2a-APP cells must be interpreted with caution, our study indicates that enhanced conversion of cholesterol to 24S-hydroxycholesterol reduces cholesterol in lipid ra s. is reduction is associated with a decreased amount of APP and PSEN1, a major component of γ-secretase, in the same microdomains. Further experiments are clearly needed to clarify how the cholesterol changes in lipid ra s that are induced by CYP46A1 overexpression a ect the recruitment and activity of PSEN1 and other components of γ-secretase complex in these microdomains.
Overall, these data demonstrate that selective overexpression of CYP46A1 in neurons can reduce Aβ peptides and amyloid deposits in mouse models of AD when the overexpression of CYP46A1 is induced before or a er the formation of amyloid plaques. Further studies are however needed to study the longterm e ect of CYP46A1 overexpression on amyloidogenic processing of APP and the e ect of this therapeutic approach on amyloid pathology at di erent pathological stages in AD mice. is work however supports that brain gene delivery of CYP46A1 gene could be of potential therapeutic interest in Alzheimer patients.
MATERIALS AND METHODS
AAV plasmid design and vectors production. Wild-type and mt CYP46A1 pcDNA plasmids were generously given by Laurent Pradier (Sano -Aventis, Paris, France). ree PCR-generated fragments containing the entire sequences of the 0.6-kb murine phosphoglycerate kinase (PGK) promoter, the 1.5-kb CYP46A1 cDNA and the 0.6-kb regulatory element of woodchuck hepatitis virus post-transcriptional regulatory element were cloned to generate pAAV5/PGK-hCYP46A1-woodchuck hepatitis virus post-transcriptional regulatory element plasmids. e functionality of each AAV plasmid was checked by transient transfection of 293T cells (data not shown). ese plasmids were used to generate AAV5/5-PGK-HACYP46A1 (referred to as AAV5-wtCYP46A1) and AAV5/5-PGK-HACYP46A1mut (referred to as AAV5-mtCYP46A1) vectors. AAV stocks were generated by transient transfection of 293T cells and puri ed using CsCl ultracentrifugation gradient. 49 Titers ranged from 4 to 9 × 10 12 vg/ml.
Transgenic mouse lines and intracerebral injections of AAVs. e APP23 transgenic mouse line ( y1-hAPP swe ) 17 was generously provided by Matthias Staufenbiel (Novartis Pharma, Basel, Switzerland). ese mice overexpress the mutated human APP 751 gene containing the Swedish double mutation (K670N-M671L) under the neuronal speci c promoter y-1. APP/PS mice were kindly given by Laurent Pradier (Aventis Pharma, Paris, France). is double transgenic mouse line overexpresses both the human mutated PSEN1 (PS1M146L) and APP (APP 695 containing the Swedish and London mutations) genes. 19 Animals were housed in a pathogen-free animal facility. e experiments were approved by the veterinary desk of INSERM and carried out in compliance with the guide for the Care and Use of Laboratory Animals (NIH publication no.85-24) and the European Communities Council Directive (86/609/EEC). In addition, the behavioral screening protocol performed on APP23 mice was approved by the Animal Ethics Committee of the University of Antwerp.
For stereotactic intracerebral AAV injection, animals were anesthetized by intraperitoneal injection of ketamine/xylazine (0.1/0.05 mg/g body weight) and positioned on a stereotactic frame (David Kopf Instruments, Tujunga, CA). Injections of vectors were performed in the cerebral cortex (two deposits) and hippocampus (one deposit) of each hemisphere with 2 µl of viral preparation (12 × 10 8 vg) using a 30-gauge blunt micropipette attached to a 10-µl Hamilton syringe (Hamilton Medical, Reno, NV) at a rate of 0.2 µl/minute. Stereotactic coordinates of injection sites from bregma were (i) anteroposterior: −0.3; mediolateral: 2; dorsoventral: −1.5 mm; (ii) anteroposterior: −2; mediolateral: 1.2; dorsoventral: −1.2 mm, and anteroposterior: −2; mediolateral: 1.2; dorsoventral: −2 mm.
APP23 and APP/PS mice were, respectively killed at 12 and 6 months. One half-brain was used for histochemistry.
e hippocampus and cerebral cortex of the other half-brain were dissected for biochemistry, gene expression and protein analysis using western blotting.
Cell lines and culture conditions. Cells were maintained in Dulbecco's modi ed Eagle's medium supplemented with 10% fetal bovine serum, 1% glutamine, and 1% penicillin and streptomycin (all from Gibco Laboratories). APPsl (containing the Swedish K670N-M671L and London V717I mutations) cDNA was obtained by PCR from APP/PS mice (Laurent Pradier, Sano -Aventis) and cloned under a pCMV promoter in a pIRES-PURO plasmid (Invitrogen, Eugene, OR). A er transfection using the E ectene tranfection kit (Qiagen, Courtaboeuf, Fance), puromycin-resistent N2a-hAPPsl cells were selected by limit dilution method and tested by PCR. N2a-APPsl cells were then stably transfected by a pcDNA-pCMV-CYP46A1 plasmid containing a neomycin-resistant selection cassette.
Determination of cholesterol and 24S-hydroxycholesterol. e quantication of cellular cholesterol was performed using the Amplex Red cholesterol assay kit (Invitrogen). For 24S-hydroxycholesterol determination, 24-hydroxycholesterol-2 H 7 (Medical Isotopes, Pelham, NH) internal standard was added to brain and cell homogenates. A er hydrolysis and extraction, samples were sulphatated, and 24S-hydroxycholesterol was quanti ed by high-performance liquid chromatography-tandem mass spectrometry (Quattro II; Micromass, Manchester, UK) using a calibration curve with electrospray ionization in the negative ion mode. Samples were loaded onto an analytical column at 0. 
Determination of A levels by enzyme-linked immunosorbent assay.
In vitro, secreted Aβ peptides were measured in the medium 48 hours a er plating the cells. In vivo, dissected cortex and hippocampus were rst homogenized in 10 mmol/l Tris-HCl bu er (pH 6.8) containing protease inhibitor cocktail (Complete; Roche, Meylan, France), adjusted to 6 mg protein/ml and 50 µl was extracted in 5 mol/l guanidine-HCl. Aβ 40 and Aβ 42 peptides were quanti ed using commercially available ELISA kits (Biosource and Innogenetics, Eugene, OR).
Western blotting.
Western blot experiments were performed using a standard protocol (10% polyacrylamide gel electrophoresis-sodium dodecyl sulfate electrophoresis), except for Aβ oligomers analyses that were done using precast CRITERION 12% Bis-Tris gels (Bio-Rad, Hercules, CA) in NuPAGE MES running bu er (Invitrogen). All samples were extracted in lysis bu er containing protease inhibitor cocktail (Complete; Roche). Primary antibodies (Supplementary Table S1) were incubated for 2 hours at room temperature, followed by species-speci c peroxidaseconjugated secondary antibodies.
e enhanced chemiluminescence method (GE Healthcare, Saclay, France) was used for revelation. Signal quanti cation was done using densitometry analysis of the scanned autoradiograms with the ImageJ 1.38x National Institutes of Health so ware.
Soluble A oligomers analyses. Dissected cortex and hippocampus were rst homogenized in a dounce homogeneizer in Tris-HCl 10 mmol/l, pH 6.8 supplemented with protease inhibitor cocktail (Complete; Roche). Protein concentration was adjusted to 6 mg/ml for all samples. A rst ultracentrifugation step (100,000 g at 4 °C) was performed to collect the Tris supernatant and the pellet was dissolved into a Tris-HCl 10 mmol/l, 2% Triton bu er (pH 6.8). Another ultracentrifugation step (100,000 g, 4 °C) allowed removing the Triton supernatant and the pellet was resuspended in a Tris-HCl 10 mmol/l, 0.5% sodium dodecyl sulfate bu er (pH 6.8). A er a last ultracentrifugation step (100,000 g at room temperature), the sodium dodecyl sulfate supernatant was collected and the pellet was directly dissolved in Blue Laemmli solution.
DRM isolation. Lipid ra s were isolated as previously described. 36 A pellet of 10 million cells was rst lysed in modi ed earth's solution bu er (25 mmol/l MES, 150 mmol/l NaCl, EDTA 1 mmol/l pH 6.5) containing 1% Triton X-100 and protease inhibitor cocktail (Complete; Roche). All steps were performed at 4 °C. e protein concentration was adjusted to 5 mg/ ml and cell lysates were brought into 40% iodixanol (OptiPrep Dendity Gradient; Sigma, Lyon, France) diluted in appropriate bu er (0.25 mol/l sucrose, 6 mmol/l EDTA, 120 mmol/l Tricine, pH 7.6). Two layers of 30% and then 20% iodixanol bu er were overlaid at the top of the ultracentrifuge tube. A er ultracentrifugation at 39,000 r.p.m. for 20 hours at 4 °C, fractions (of 1 ml) were collected and analyzed by western blotting according to standard protocol. e detection of otillin 2 was used to identify DRM fractions.
Quantitative RT-PCR. mRNA extraction from cells or tissues was performed using the RNAble kit (Eurobio Laboratories, Les Ulis, France). Realtime quantitative RT-PCR on the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA) was performed as described. 50 As an endogenous RNA control, we quanti ed transcripts of the TATA box-binding protein (TBP) gene . e amount of target transcript (N target ) was normalized based on the basis of the TBP content of each sample and was subsequently normalized to a basal mRNA level with the equation: N 2 target t C , where C t is the C t value of the target gene minus the C t value of the TBP gene. Primers are listed in Supplementary  Table S2 .
Behavioral analysis. e MWM setting consisted of a circular pool (diameter: 150 cm, height: 30 cm) lled with opaci ed water (nontoxic natural paint), kept at 25 °C, and surrounded by invariable visual extramaze cues. A round acrylic glass platform (diameter: 15 cm) was placed 1 cm below the water surface at a xed position in one of the quadrants. e acquisition phase comprised eight trial blocks of four daily trials semirandomly starting from four di erent positions around the border of the maze with 15-minutes intertrial intervals. In case a mouse was unable to reach the platform within 120 seconds, it was placed on the platform during 15 seconds before being returned to its home cage. Swimming trajectories were recorded using a computerized video-tracking system (EthoVision, Noldus, e Netherlands) logging path length, escape latency, and swim speed. Four days a er nishing the acquisition phase, a probe trial was performed. e platform was removed from the maze, and each mouse was allowed to swim freely for 100 seconds. Spatial accuracy was expressed as the percentage of time spent in each quadrant of the MWM, and the number of crossings through the target position, i.e., the speci c location of the platform during the acquisition phase.
Statistics for behavioral analysis: Two-way repeated measures-analysis of variance (repeated measures-analysis of variance), with treatment and trial block as possible sources of variation, combined with Tukey's honestly signi cantly di erent post hoc procedure, assessed the signi cance of di erences between mean scores during the acquisition phase. Spatial acuity during the probe trial was probed using two-way analysis of variance with Tukey's honestly signi cantly di erent test. Two-tailed Student's t-test (t-test) was used to evaluate di erences in the number of entries through the previous target position and path length during probe trial. All statistics were performed using Sigmastat so ware (SPSS, Erkrath, Germany) with the level of probability set at 95%.
Immunohistochemistry and microscopy analyses. Anesthetized animals were transcardially infused with phosphate-bu ered saline. For biochemical analyses, le cortex and hippocampus were dissected, weighted, and nitrogen frozen. e right hemi-brain was post xed in 4% paraformaldehyde in phosphate-bu ered saline for 24 hours and para n embedded. Five-micrometer sections were sequentially (i) depara ned in xylene, (ii) rehydrated in ethanol, (iii) permeabilized in phosphate-bu ered saline 0.05% saponine, (iv) blocked in phosphate-bu ered saline 0.01% saponine, 5% normal goat serum, and (v) incubated overnight with the primary antibody. For amyloid plaques labeling of amyloid plaques with the mouse monoclonal 4G8 antibody, a treatment with 80% formic acid for 30 minutes was performed. A step of antigen retrieval in citric acid (0.1 mol/l)/sodium citrate (0.1 mol/l) bu er was necessary for several antibodies. Secondary antibodies were applied 1 hour at room temperature. All the antibodies are listed in Supplementary Table S1 . Images were taken with a Nikon microscope (Eclipse 800; Nikon, Champigny-sur-Marne, France) and a digital QIMAGING camera (CCD QICAM cooled plus RGB lter pixel 4.65 × 4.65 µm 2 ; QIMAGING, Surrey, BC, Canada). Control and test slices were processed the same day and under the same condition.
Stereological analyses were performed on three section levels per mouse (the rst level being located at 50 µm from the medial axis and the two next levels at 150 and 250 µm, respectively), with three to ve contiguous slices per level. To determine the surface and number of amyloid deposits in anatomic region of interest, the Histolab image analyzer so ware (Microvision Instruments, Paris, France) was set up to automatically detect in a blind fahsion 3,3 -diaminobenzidine-labeled deposits. Plaques for which the intensity was not su cient above the background for proper thresholding were not considered. e parameters setting remained unchanged for all analyses. Each 3,3 -diaminobenzidine positive object was considered as an amyloid plaque and the image analyzer directly measured its surface or number. For each slice, the amyloid deposits quanti cation was then reported to the surface of the cortex and hippocampus of the same slice. e count of glial brillary acidic protein and Iba-1 positive cells was performed according to the same procedure.
Statistical analyses. All statistical procedures, except for behavioral analyses, were performed using StatView 5.0 and JMP 7.0 so wares for Macintosh (SAS, Cary, NC). In vitro data were analyzed by analysis of variance followed by Student's t-test post hoc multiple comparison when appropriate. Because of small animal groups, data from in vivo experiments were analyzed using the nonparametric Mann-Whitney U-test. Error of the mean values in the text and bars on graphs stand for SEM. Figure S1 . Expression of CYP46A1 gene decreases A 40/42 peptide secretion in murine neuroblastoid N2a cells expressing mutated human APP (APPsl). Table S1 . List of primary antibodies. Table S2 . List of primers used for real-time RT-PCR.
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